

# Marco Russano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5728264/publications.pdf>

Version: 2024-02-01

43  
papers

1,845  
citations

471509

17  
h-index

361022

35  
g-index

47  
all docs

47  
docs citations

47  
times ranked

3129  
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
2	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. Journal of Experimental and Clinical Cancer Research, 2020, 39, 95.	8.6	147
3	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
4	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
5	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
6	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Advances in Therapy, 2020, 37, 1145-1155.	2.9	102
7	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
8	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
9	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
10	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
11	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	6.4	69
12	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$ : a multicenter study with external validation. , 2020, 8, e001403.		57
13	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	2.6	50
14	Prognostic and predictive factors in pancreatic cancer. Oncotarget, 2020, 11, 924-941.	1.8	46
15	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
16	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	1.9	30
17	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	3.7	27
18	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. <i>Cancers</i> , 2021, 13, 652.	3.7	19
20	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq$ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	2.8	19
21	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 959-964.	3.1	18
22	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103404.	4.4	18
23	Treatment of Metastatic Colorectal Cancer Patients $\geq$ 75 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016, 11, e0157751.	2.5	17
24	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
25	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
26	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1261-1274.	3.1	12
27	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12
28	Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?. <i>Journal of Thoracic Oncology</i> , 2020, 15, e105-e106.	1.1	12
29	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
30	Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. <i>Oncotarget</i> , 2017, 8, 59986-59990.	1.8	11
31	Pazopanib and pancreatic toxicity: a case report. <i>BMC Research Notes</i> , 2015, 8, 196.	1.4	9
32	Facing SARS-CoV-2 outbreak in immunotherapy era. <i>Future Oncology</i> , 2020, 16, 1475-1485.	2.4	9
33	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	4.6	9
34	Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. <i>Supportive Care in Cancer</i> , 2013, 21, 2955-2956.	2.2	8
35	Impact of Smoking Cessation Treatment on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2015, 10, 342-351.	1.6	8
36	Cabozantinib and apixaban: a hitherto unreported interaction. <i>Experimental Hematology and Oncology</i> , 2019, 8, 22.	5.0	7

#	ARTICLE	IF	CITATIONS
37	â€˜Old' and â€˜new' drugs for the treatment of cancer pain. Expert Opinion on Pharmacotherapy, 2013, 14, 425-433.	1.8	6
38	Bone metastases in biliary cancers: A multicenter retrospective survey. Journal of Bone Oncology, 2018, 12, 33-37.	2.4	5
39	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	17.0	5
40	Steroid-refractory immune related hepatitis may hide viral re-activation. Future Science OA, 2020, 6, FSO614.	1.9	2
41	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy, 2022, 34, 123-132.	1.5	1
42	Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer. Clinical Lung Cancer, 2021, 22, e137-e138.	2.6	0
43	Response to: Successful afatinib rechallenge in a patient with nonâ€small cell lung cancer harboring EGFR G719C and S768I mutations. Thoracic Cancer, 2021, 12, 1791-1792.	1.9	0